Preclinical results combining our T-SIGn vector & @bluebirdbio's CAR-T therapy presented at
#AACR21 showed synergistic activity between the two therapies, validating the potential of our T-SIGn vectors to be used with various proven
#IO therapies.
bit.ly/3cIqumo